Comprehensive registry of esophageal cancer in Japan, 2013

Abstract

Background Esophageal cancer is the eighth most common cause of cancer mortality in Japan. More than 11,000 people had died from esophageal cancer in 2018. The Japan Esophageal Society has collected the data on patients' characteristics, performed treatment, and outcomes annually. Methods We analyzed the data of patients who had first visited the participating hospitals in 2013. In 2019, the data collection method was changed from an electronic submission to a web-based data collection using the National Clinical Database (NCD). Japanese Classification of Esophageal Cancer 10th by the Japan Esophageal Society (JES) and UICC TNM Classification 7th were used for cancer staging Results A total of 8019 cases were registered from 334 institutions in Japan. Squamous cell carcinoma and adenocarcinoma accounted for 87.8% and 6.3%, respectively. The 5-year survival rates of patients treated using endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, or esophagectomy were 88.3%, 32.4%, 24.4%, and 59.3%, respectively. Esophagectomy was performed in 4910 cases. The operative and the hospital mortality rates were 0.77% and 1.98%, respectively. The survival curves showed a good discriminatory ability both in the clinical and pathologic stages by the JES system. The 5-year survival rate of patients with pStage IV in the UICC classification that included patients with supraclavicular node metastasis was better than that of patients with pStage IVb in JES classification. Conclusion We hope this report contributes to improving all aspects of the diagnosis and treatment of esophageal cancer in Japan.

Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma

“…2 Data from the 2012 comprehensive registry of esophageal cancer in Japan showed that 2300 (28.8%) of 7999 patients with esophageal cancer had been diagnosed as having a stage IA (Union for International Cancer Control 7th Q6 ) malignancy. 3 In the guidelines of the Japan Esophageal Society, the European Society of Medical Oncology, and the National Comprehensive Cancer Network, endoscopic resection is recommended for mucosal (T1a) lesions, whereas surgical resection is recommended for patients with submucosal (T1b) lesions and definitive chemoradiotherapy (CRT) is recommended for patients who are unable or unwilling to undergo surgery. [4][5][6] According to previous reports, a 5-year overall survival rate of 70%-80% for stage IA esophageal squamous cell carcinoma (ESCC) is expected.…”

Development and Validation of a Robust Immune-Related Prognostic Signature for Gastric Cancer

“…Increasing evidence has shown that connective tissue growth factor (CTGF) is a multifunctional signal regulator that promotes the occurrence, progression, and metastasis of cancer by regulating epithelial-mesenchymal transition (EMT), invasion, migration, cell proliferation, and drug resistance [ 38 ]. Esophageal cancer (ESCA) was accompanied by high upregulation of ESM1, which could be partly explained by cell proliferation and migration and the regulation of the Janus kinase (JAK) signaling pathway [ 39 ]. As a protein-coding gene, inhibin subunit β B (INHBB) is involved in the synthesis of transforming growth factor- β (TGF- β ) family members.…”

Postoperative solitary liver metastasis from esophageal squamous cell carcinoma achieving a clinical complete response to chemotherapy with cisplatin and 5‑fluorouracil followed by stereotactic body radiotherapy: A case report

“…Due to the progression of neoadjuvant treatment strategies and surgical procedures, 3- and 5-year survival rates of patients who underwent esophagectomy with no residual tumors improved to 71.4 and 62.8%, respectively ( 1 ). However, recurrence still occurs in 28-56% of patients who underwent radical resection of esophageal cancer, with a median time to recurrence of 10-12 months ( 2 , 3 ).…”